Executive summary
The EU pharmaceutical framework — Directive 2001/83/EC and Regulation (EC) 726/2004 — governs peptides as medicinal products. The European Medicines Agency (EMA) evaluates centrally authorised peptide drugs; individual member states authorise others through mutual recognition or decentralised procedures. Pharmacy compounding is regulated at member-state level. The EU Cosmetics Regulation (EC) 1223/2009 covers peptides in cosmetic products.
Authorities and legal categories
European Commission: grants and suspends centralised marketing authorisations based on EMA scientific opinion.
EMA: scientific evaluation, pharmacovigilance, guideline development.
National competent authorities (e.g., BfArM/DE, ANSM/FR, AIFA/IT, AEMPS/ES): national authorisation, MRP/DCP, enforcement, pharmacy regulation.
MHRA (UK): a separate post-Brexit regulator; see the dedicated UK page.
EDQM (Council of Europe, not EU): European Pharmacopoeia standards and CEP certification for peptide APIs.
EUDA (formerly EMCDDA): early warning system for new psychoactive substances, including some peptide analogues.
Core instruments:
Directive 2001/83/EC — Community code on medicinal products.
Regulation (EC) 726/2004 — centralised procedure.
Regulation (EC) 1223/2009 — cosmetics.
Regulation (EU) 2015/2283 — novel foods.
Directive 2011/62/EU — falsified medicines, online sale logo.
Regulation (EU) 2016/161 — safety features (unique identifier + anti-tamper device).
- Mandatory centralized route: EMA scientific opinion, then European Commission decision.
- Other routes: national, mutual-recognition, or decentralized procedures through national competent authorities.
- Both routes yield an authorized product with a defined jurisdictional scope.
- The MHRA and United Kingdom form a separate post-Brexit system.
Approved medicines
Centrally authorised peptide drugs include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), insulin analogues, teriparatide, leuprolide, octreotide, and many others.
Biologically derived peptides (rDNA production) fall under the mandatory centralised procedure. Chemically synthesised peptides may use the centralised procedure voluntarily or follow national/MRP/DCP pathways.
Source: EMA Medicines Search, https://www.ema.europa.eu/en/medicines
| Route | Decision makers | When page says it applies | Geographic result | Caveat |
|---|---|---|---|---|
| Mandatory centralised | EMA scientific evaluation followed by a European Commission decision | Biologically derived peptides produced by recombinant DNA | A centrally authorised product with the scope stated in its authorization | EMA provides the opinion; it does not itself grant the Commission authorization |
| Voluntary centralised | EMA and European Commission | Chemically synthesised peptides may elect this route | A centrally authorised product with the stated scope | Eligibility and current product record still require verification |
| National | National competent authority | Products handled under a national route | Authorization in the named national jurisdiction | National authorization is not a universal EEA record |
| Mutual-recognition or decentralised | Participating national competent authorities | Chemically synthesised peptides may follow MRP or DCP | Authorization across the participating jurisdictions | The participating states and final national records must be checked |
Investigational use
Clinical trials require authorisation under the Clinical Trials Regulation (EU) 536/2014 (effective 31 January 2022). Sponsors must submit a Clinical Trial Application through the EU Clinical Trials Information System (CTIS).
Compounding/manufacturing
Article 3(1) of Directive 2001/83/EC exempts magistral formulae (prepared in a pharmacy per a prescription for an identified patient) from marketing authorisation.
Article 3(2) exempts officinal formulae (prepared per pharmacopoeia, supplied directly to the pharmacy's own patients).
CJEU judgment Abcur (C-544/13 and C-545/13): prescription must be prior to preparation; patient must be identified before production. Stock preparation for unspecified patients is industrial manufacture, not compounding.
Council of Europe Resolution CM/Res(2011)1 provides non-binding quality guidance for pharmacy preparations.
Member state variation is significant: Germany, France, and the Netherlands have developed pharmacy preparation sectors; others restrict compounding to extemporaneous only. Peptide compounding is highly variable.
Import, sale, advertising, and online supply
Import: requires a Manufacturing/Import Authorisation (MIA). Every batch must be certified by a Qualified Person (QP) in the EU/EEA. Active substances must be manufactured to EU-equivalent GMP standards.
Online sale: the Falsified Medicines Directive (2011/62/EU) requires the common logo on every webpage offering medicinal products. Clicking the logo must redirect to the national competent authority's register of authorised online retailers. Most member states prohibit online sale of prescription-only medicines.
Advertising: prescription-only medicines cannot be advertised to the public (Directive 2001/83/EC, Title VIII).
Research-use-only products
No specific EU-level exemption exists for "research chemicals." If a product meets the medicinal product definition (making therapeutic or physiological claims), it is a medicine and requires a marketing authorisation. Member state enforcement agencies can take action under national law.
Sport/anti-doping overlay
The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. 定義の出典: WADA and sport regulation brief · 用語集 Prohibited List applies through national anti-doping organisations in each EU/EEA member state.
Cosmetics
Regulation (EC) 1223/2009 covers peptide ingredients in cosmetics. Peptide ingredients must be listed in INCI. The boundary with medicinal products is determined by claims and physiological effect. Regulation (EU) 2024/858 addressed nanomaterials in cosmetics, specifically banning acetyl heptapeptide-9 colloidal gold (nano) and acetyl tetrapeptide-17 colloidal platinum (nano) from the EU market as of February 2025 due to insufficient safety data.
Source: https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en
Novel foods
Regulation (EU) 2015/2283 covers novel foods. Peptide hydrolysates and isolated peptides may require novel food authorisation (EFSA assessment + Commission implementing regulation) if not consumed in the EU to a significant degree before May 15, 1997. The boundary with medicinal products applies — the same substance cannot be both a medicine and a food.
| Category | Governing framework | Medicine-claim boundary |
|---|---|---|
| Cosmetics | Regulation (EC) 1223/2009 | Claims to treat or prevent disease, or a pharmacological effect, can trigger medicinal-product classification |
| Novel foods | Regulation (EU) 2015/2283 | A product cannot be treated as both a medicine and a food; composition, consumption history, and claims must be assessed |
Enforcement examples and uncertainty
Member state enforcement against peptide sales varies widely; some have active programmes targeting "research chemical" websites, others do not.
The distinction between compounding (Art. 3 exemption) and industrial manufacture remains subject to case-by-case interpretation post-Abcur.
Compounding of GLP-1 peptides using imported bulk substances raises quality and legal questions in most member states.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: United Kingdom, cross-border supply, approved-product label index, and WADA and sport.
Primary sources
Directive 2001/83/EC (consolidated). https://eur-lex.europa.eu/eli/dir/2001/83
Regulation (EC) 726/2004 (consolidated). https://eur-lex.europa.eu/eli/reg/2004/726
Regulation (EC) 1223/2009 (consolidated). https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX%3A02009R1223-20260501
Regulation (EU) 2015/2283 (novel foods). https://eur-lex.europa.eu/eli/reg/2015/2283
Directive 2011/62/EU (FMD). https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32011L0062
EMA Medicines Search. https://www.ema.europa.eu/en/medicines
EMA Synthetic Peptide Guideline (effective June 2026). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline
CJEU Abcur (C-544/13 and C-545/13). https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=ecli:ECLI:EU:C:2015:481
EDQM CEP. https://www.edqm.eu/en/certification
CM/Res(2011)1. https://rm.coe.int/168065c132